公开(公告)号：US20240360215A1

公开(公告)日：2024-10-31

申请号：US18645760

申请日：2024-04-25

申请人： The Regents of the University of California

发明人： James L. Rubenstein

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K31/454 ,  A61K31/519 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61K9/0019 ,  A61K31/454 ,  A61K31/519 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24

摘要： The disclosure provides a method of treating CNS lymphomas using a combination therapy comprising an anti-CD19 antibody and an immunomodulatory imide drug.

公开(公告)号：US20240360075A1

公开(公告)日：2024-10-31

申请号：US18640931

申请日：2024-04-19

申请人： ALCON INC.

发明人： Heeren M. Gordhan ,  Mitchell A. deLong ,  Jill M. Sturdivant ,  David Archer Ellis ,  Cynthia L. Lichorowic

IPC分类号： C07C233/60 ,  A61K9/00 ,  A61K31/16 ,  A61K31/165 ,  A61K31/167 ,  A61K31/175 ,  A61K31/192 ,  A61K31/27 ,  A61K31/277 ,  A61K31/337 ,  A61K31/341 ,  A61K31/343 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/40 ,  A61K31/415 ,  A61K31/425 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/5375 ,  A61K31/69 ,  A61K47/12 ,  A61K47/18 ,  A61K47/38 ,  C07C231/02 ,  C07C233/58 ,  C07C233/59 ,  C07C233/62 ,  C07C233/63 ,  C07C235/14 ,  C07C235/56 ,  C07C237/24 ,  C07C271/20 ,  C07C271/24 ,  C07C279/22 ,  C07C315/04 ,  C07C317/30 ,  C07D205/04 ,  C07D207/09 ,  C07D209/54 ,  C07D211/58 ,  C07D213/75 ,  C07D213/79 ,  C07D231/40 ,  C07D239/42 ,  C07D263/04 ,  C07D263/56 ,  C07D265/36 ,  C07D275/03 ,  C07D277/46 ,  C07D295/088 ,  C07D295/135 ,  C07D295/32 ,  C07D305/06 ,  C07D305/08 ,  C07D305/14 ,  C07D307/22 ,  C07D307/94 ,  C07D309/14 ,  C07D311/58 ,  C07D335/02 ,  C07F5/02

CPC分类号： C07C233/60 ,  A61K9/0048 ,  A61K31/16 ,  A61K31/165 ,  A61K31/167 ,  A61K31/175 ,  A61K31/192 ,  A61K31/27 ,  A61K31/277 ,  A61K31/337 ,  A61K31/341 ,  A61K31/343 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/40 ,  A61K31/415 ,  A61K31/425 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/5375 ,  A61K31/69 ,  A61K47/12 ,  A61K47/183 ,  A61K47/186 ,  A61K47/38 ,  C07C231/02 ,  C07C233/58 ,  C07C233/59 ,  C07C233/62 ,  C07C233/63 ,  C07C235/14 ,  C07C235/56 ,  C07C237/24 ,  C07C271/20 ,  C07C271/24 ,  C07C279/22 ,  C07C315/04 ,  C07C317/30 ,  C07D205/04 ,  C07D207/09 ,  C07D209/54 ,  C07D211/58 ,  C07D213/75 ,  C07D213/79 ,  C07D231/40 ,  C07D239/42 ,  C07D263/04 ,  C07D263/56 ,  C07D265/36 ,  C07D275/03 ,  C07D277/46 ,  C07D295/088 ,  C07D295/135 ,  C07D295/32 ,  C07D305/06 ,  C07D305/08 ,  C07D305/14 ,  C07D307/22 ,  C07D307/94 ,  C07D309/14 ,  C07D311/58 ,  C07D335/02 ,  C07F5/025 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/18 ,  C07C2602/38 ,  C07C2602/42 ,  C07C2602/50

摘要： Described herein are modified monoterpene TRPM8 activating compounds. In particular, provided herein are compounds that affect the function of ion channels in a cell, and are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth, such as cancers.

公开(公告)号：US20240360071A1

公开(公告)日：2024-10-31

申请号：US18386906

申请日：2023-11-03

申请人： Orphalan S.A.

发明人： Timothy James Morley ,  Ronnie Maxwell Lawrence ,  Naseem Amin

IPC分类号： C07C211/14 ,  A61K9/00 ,  C07C209/84

CPC分类号： C07C211/14 ,  C07C209/84 ,  A61K9/0053 ,  C07B2200/13

摘要： The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

公开(公告)号：US20240358804A1

公开(公告)日：2024-10-31

申请号：US18397180

申请日：2023-12-27

申请人： LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER ,  THE UNIVERSITY OF UTAH

发明人： Ashraf S. IBRAHIM ,  June L. ROUND ,  Kyla OST

IPC分类号： A61K39/00 ,  A61K9/00 ,  A61P1/00

CPC分类号： A61K39/0002 ,  A61K9/0019 ,  A61K9/0073 ,  A61P1/00 ,  A61K2039/545

摘要： The invention provides a vaccine against inflammatory bowel disease (IBD), such as Crohn's disease, ulcerative colitis, and the like. The vaccine comprises a polypeptide comprising a Candida adhesin antigen, typically an isolated agglutinin-like sequence (Als) protein antigen, formulated with one or more pharmaceutically acceptable carriers or excipients.

公开(公告)号：US20240358752A1

公开(公告)日：2024-10-31

申请号：US18674944

申请日：2024-05-27

申请人： Andrea Jochheim-Richter

发明人： Herbert STADLER ,  Stefan SCHNEIDER ,  Andrea JOCHHEIM-RICHTER ,  Ingeborg SILLABER

IPC分类号： A61K35/16 ,  A61K9/00 ,  A61K9/06 ,  A61P27/02

CPC分类号： A61K35/16 ,  A61K9/0048 ,  A61K9/06 ,  A61P27/02

摘要： Provided are novel biologically active blood fractions that can be used for the treatment of damaged epithelial surfaces and that are nanofilterable as well as corresponding compositions and eye drops and methods of their manufacture.

公开(公告)号：US20240358725A1

公开(公告)日：2024-10-31

申请号：US18682693

申请日：2022-08-10

申请人： AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

发明人： Babak BABAN ,  Jack YU

IPC分类号： A61K31/00 ,  A61K9/00 ,  A61P35/00

CPC分类号： A61K31/658 ,  A61K9/008 ,  A61P35/00

摘要： A method of reducing tumor size in a subject in need thereof, comprising administering to the subject an effective amount of cannabidiol effective to inhibit tumor growth.

公开(公告)号：US20240358716A1

公开(公告)日：2024-10-31

申请号：US18647921

申请日：2024-04-26

申请人： Citius Pharmaceuticals, Inc.

发明人： Vijendra Nalamothu ,  Srikanth Manne ,  Sindhu Addala

IPC分类号： A61K31/573 ,  A61K9/00 ,  A61K9/06 ,  A61K31/167 ,  A61K47/10 ,  A61K47/34 ,  A61K47/38 ,  A61P9/14

CPC分类号： A61K31/573 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/167 ,  A61K47/10 ,  A61K47/34 ,  A61K47/38 ,  A61P9/14

摘要： The disclosure relates to pharmaceutical formulations comprising of lidocaine and halobetasol propionate, methods of making such formulations, and methods of using such formulations in the treatment of hemorrhoids.

公开(公告)号：US20240358706A1

公开(公告)日：2024-10-31

申请号：US18676591

申请日：2024-05-29

申请人： Ipsen Biopharm Ltd.

发明人： Eliel Bayever ,  Sarah F. Blanchette ,  Jonathan Basil Fitzgerald ,  Daniel F. Gaddy ,  Bart S. Hendriks ,  Ashish Kalra ,  Helen Lee

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61K9/127 ,  A61K31/282 ,  A61K31/436 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K47/20

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/282 ,  A61K31/436 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K47/20 ,  A61K2300/00

摘要： Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

公开(公告)号：US20240358664A1

公开(公告)日：2024-10-31

申请号：US18318697

申请日：2023-05-16

申请人： PYROS PHARMACEUTICALS, INC.

发明人： Nrupa Patel ,  Raenel V. Gibson ,  Michael M. Smith ,  Edwin Urrutia

IPC分类号： A61K31/197 ,  A61J1/14 ,  A61J7/00 ,  A61K9/00 ,  A61K47/14 ,  A61K47/26 ,  A61K47/46

CPC分类号： A61K31/197 ,  A61J1/1468 ,  A61J7/0053 ,  A61K9/0095 ,  A61K47/14 ,  A61K47/26 ,  A61K47/46

摘要： The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related compound A that are both not more than 0.04% at, or prior to, six months. In some embodiments, the composition has improved stability and patient compliance. In some embodiments, the compositions may be advantageous for the patients having swallowing difficulties or when the patients are unable to take solid oral dosage forms. In some embodiments, the composition improves compliance with ketogenic diet.

公开(公告)号：US20240358649A1

公开(公告)日：2024-10-31

申请号：US18735277

申请日：2024-06-06

申请人： Pinata Holdings Inc.

发明人： Michael OGBURN ,  Christopher PRICE

IPC分类号： A61K9/50 ,  A61K9/00 ,  A61K31/155 ,  A61K31/568 ,  A61K38/26 ,  A61K45/06

CPC分类号： A61K9/5042 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/5089 ,  A61K31/155 ,  A61K31/568 ,  A61K38/26 ,  A61K45/06

摘要： Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions and kits described herein. The pharmaceutical compositions described herein are powdery pharmaceutical compositions. The powdery pharmaceutical compositions may be administered by an inhaler device described herein. The powdery pharmaceutical compositions may be administered by gummies described herein.